| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5cd84f92e5e2ff95dfd19e4e329db3b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a0ae2617cea9c523d19ba971921b64c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_170dea426c1050c11847e84481bed07f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfd243dc2e9ce9379c20a6803414238c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9d21497a52a908bef4bafdf9ab4be06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4cf9094999867ff50642cbf3d8eec26 |
| publicationDate |
2015-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201522368-A |
| titleOfInvention |
Anti-tissue factor pathway inhibitor prodrug antibody |
| abstract |
The present invention provides prodrug antibodies that specifically bind to a tissue factor pathway inhibitor (TFPI) only after exposure to a protease of the coagulation cascade. The prodrug antibody can be used to treat bleeding disorders such as hemophilia. When used in such treatments, these prodrug antibodies show an increase in half-life relative to other anti-TFPI antibodies while reducing the likelihood of side effects such as thrombosis. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |